Predictors of pulmonary tuberculosis treatment outcomes in South Korea: A prospective cohort study, 2005-2012

Hongjo Choi, Myungsun Lee, Ray Y. Chen, Youngran Kim, Soyoung Yoon, Joon S. Joh, Seung K. Park, Lori E. Dodd, Jongseok Lee, Taeksun Song, Ying Cai, Lisa C. Goldfeder, Laura E. Via, Matthew W. Carroll, Clifton E. Barry, Sang Nae Cho

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)

Abstract

Background: Tuberculosis remains an important health concern in many countries. The aim of this study was to identify predictors of unfavorable outcomes at the end of treatment (EOT) and at the end of study (EOS; 40 months after EOT) in South Korea.Methods: New or previously treated tuberculosis patients were recruited into a prospective observational cohort study at two hospitals in South Korea. To identify predictors of unfavorable outcomes at EOT and EOS, logistic regression analysis was performed.Results: The proportion of multidrug-resistant tuberculosis (MDR-TB) was 8.2% in new cases and 57.9% in previously treated cases. Of new cases, 68.6% were cured, as were 40.7% of previously treated cases. At EOT, diabetes, ≥3 previous TB episodes, ≥1 significant regimen change, and MDR-TB were significantly associated with treatment failure or death. At EOS, age ≥35, body-mass index (BMI) <18.5, diabetes, and MDR-TB were significantly associated with treatment failure, death, or relapse. Among cases that were cured at EOT, age ≥50 and a BMI <18.5 were associated with subsequent death or relapse during follow-up to EOS. Treatment interruption was associated with service sector employees or laborers, bilateral lesions on chest X-ray, and previous treatment failure or treatment interruption history.Conclusions: Risk factors for poor treatment outcomes at EOT and EOS include both patient factors (diabetes status, age, BMI) and disease factors (history of multiple previous treatment episodes, MDR-TB). In this longitudinal, observational cohort study, diabetes mellitus and MDR-TB were risk factors for poor treatment outcomes and relapse. Measures to help ensure that the first tuberculosis treatment episode is also the last one may improve treatment outcomes.Trial registration: ClinicalTrials.gov ID: NCT00341601.

Original languageEnglish
Article number360
JournalBMC Infectious Diseases
Volume14
Issue number1
DOIs
Publication statusPublished - 2014 Jul 2

Bibliographical note

Funding Information:
This study was supported (in part) by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health (NIH), and (in part) by continuous support from the Korean Centers for Disease Control of the Korean Ministry of Health and Welfare to the International Tuberculosis Research Center. Through authors RYC, LED, YC, LCG, LEV, MWC, and CEB, the NIAID, NIH was involved in the design, collection, analysis, and interpretation of data; in writing the manuscript; and in the decision to submit for publication. The Korean Centers for Disease Control was not involved in the design, collection, analysis, and interpretation of data; in writing the manuscript; and in the decision to submit for publication. We would like to thank the patients who enrolled in this research study and the clinical staff who supported the trial.

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Predictors of pulmonary tuberculosis treatment outcomes in South Korea: A prospective cohort study, 2005-2012'. Together they form a unique fingerprint.

Cite this